Changshan Pharmaceutical announced that the cumulative deviation value of the company's stock closing price increase exceeded 30% for two consecutive trading days. The cumulative stock price increase from May 6 to June 9 reached 147.69%, which seriously deviated from the growth rate of the same industry and the GEM Composite Index. The company's marketing license application for epenatide injections for type 2 diabetes has been accepted, but there are many follow-up steps, and there is uncertainty about approval for marketing and approval timing. In addition, clinical trial applications for ipenatide injections intended for weight loss have also been accepted, but there is uncertainty about whether an approval notice can be obtained.

Changshan Pharmaceutical announced that the cumulative deviation value of the company's stock closing price increase exceeded 30% for two consecutive trading days. The cumulative stock price increase from May 6 to June 9 reached 147.69%, which seriously deviated from the growth rate of the same industry and the GEM Composite Index. The company's marketing license application for epenatide injections for type 2 diabetes has been accepted, but there are many follow-up steps, and there is uncertainty about approval for marketing and approval timing. In addition, clinical trial applications for ipenatide injections intended for weight loss have also been accepted, but there is uncertainty about whether an approval notice can be obtained.